Walleye Capital LLC Inozyme Pharma, Inc. Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$4.09 - $7.0 $842,593 - $1.44 Million	-206,013 Reduced 85.46%	35,058 $147,000
Q2 2023 Aug 14, 2023	BUY	$4.93 - $6.74 $1.19 Million - $1.62 Million	241,071 New	241,071 $1.34 Million
Q3 2022 Nov 14, 2022	BUY	$2.57 - $5.45 $41,343 - $87,674	16,087 Added 15.86%	117,529 $315,000
Q2 2022 Aug 08, 2022	BUY	$3.2 - $5.96 $324,614 - $604,594	101,442 New	101,442 $484,000
Q1 2022 May 16, 2022	SELL	$3.87 - $7.55 $60,325 - $117,689	-15,588 Closed	0 $0
Q4 2021 Mar 03, 2022	BUY	$5.58 - $11.5 $86,981 - $179,262	15,588 New	15,588 $106,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $121M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.